on ExPLoRNA Therapeutics Sp. Z O. O.
ExploRNA Therapeutics Forms Strategic Partnership with Łukasiewicz - IChP
ExploRNA Therapeutics, a leader in mRNA capping technologies, has partnered with Łukasiewicz Research Network – Industrial Chemistry Institute (IChP) to enhance Good Manufacturing Practice (GMP) production of its mRNA cap analogs. This collaboration aims to supply crucial raw materials for mRNA therapeutics and vaccines.
The demand for high-quality mRNA components is surging due to advancements in biopharmaceuticals. Co-transcriptional capping is vital for drug yield and quality. Joining forces with Łukasiewicz - IChP, renowned for chemical synthesis expertise, ExploRNA will offer superior cap analogs to its partners.
"This partnership with Łukasiewicz - IChP is a critical growth milestone," said Prof. Jacek Jemielity, CEO of ExploRNA. The GMP-grade material production supports ExploRNA's strategy from research to commercialization.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ExPLoRNA Therapeutics Sp. Z O. O. news